ReviewJournal of translational medicine2026
Navigating AI and machine learning in cancer research: an end-to-end translational framework.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decision-curve analysis should be a bridge, not an endpoint, for clinical artificial intelligence in oncology.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex and heterogeneous disease that is characterized by multi-level biological variability. Advances in high-throughput technologies have led to large-scale, high-dimensional data sets in cancer research, creating a pressing need for powerful computational techniques for successful data analysis. Current techniques may be inadequate for this purpose, thus underscoring the potential of artificial intelligence (AI) and machine learning (ML) for successful data analysis. This review provides a comprehensive pipeline for artificial intelligence/machine learning in cancer research, including preclinical research, clinical decision support, and real-world implementation. It emphasizes several important technologies, data integration, and implementation challenges. The review critically examines multi-omics fusion architectures, regularization-based machine learning, batch-effect harmonization, explainable AI, and federated learning, while addressing translational barriers including algorithmic bias, covariate drift, and regulatory asynchrony across Indian, US, and EU frameworks. Anchored by Decision Curve Analysis as a clinical utility benchmark, this narrative framework establishes that meaningful progress in precision oncology, early detection, and patient outcomes demands not only predictive accuracy but also externally validated, population-representative, and governance-compliant AI systems capable of sustained real-world oncology impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.